Adiponectin levels differentiate metabolically healthy vs unhealthy among obese and nonobese white individuals

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 11, 2015, Pages 4172-4180

  Ahl, Scott ^a   Guenther, Mitchell ^a   Zhao, Shi ^a   James, Roland ^a   Marks, Jacqueline ^a   Szabo, Aniko ^a   Kidambi, Srividya ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; LIPID;

ADULT; ARTICLE; BODY MASS; CAUCASIAN; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISORDERS OF HORMONE METABOLISM; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERADIPONECTINEMIA; HYPERTENSION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; WAIST HIP RATIO; BLOOD; COMPLICATION; WEIGHT REDUCTION;

ADIPONECTIN; ADIPOSITY; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; CYTOKINES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INSULIN RESISTANCE; LIPIDS; MALE; METABOLIC DISEASES; OBESITY; WAIST-HIP RATIO; WEIGHT LOSS;

EID: 84958658346     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-2765     Document Type: Article

References (46)

1. Clearfield M, Pearce M, Nibbe Y, Crotty D, Wagner A. The "new deadly quartet" for cardiovascular disease in the 21st century: Obesity, metabolic syndrome, inflammation and climate change: How does statin therapy fit into this equation? Curr Atheroscler Rep. 2014;16(1):380.
2. McGown C, Birerdinc A, Younossi ZM. Adipose tissue as an endocrine organ. Clin Liver Dis. 2014;18(1):41-58.
3. Robinson K, Prins J, Venkatesh B. Clinical review: Adiponectin biology and its role in inflammation and critical illness. Crit Care. 2011;15(2):221.
4. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: An adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab. 2002;13(2):84-89.
5. Heidemann C, Sun Q, vanDamRM,et al. Total and high-molecularweight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med. 2008;149(5):307-316.
6. Hivert MF, Sullivan LM, Fox CS, et al. Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J Clin Endocrinol Metab. 2008;93(8):3165-3172.
7. Trujillo ME, Scherer PE. Adiponectin-Journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med. 2005;257(2):167-175.
8. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86(5):1930-1935.
9. Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: A systematic review and meta-analysis. Metabolism. 2011;60(3):313-326.
10. Doumatey AP, Bentley AR, Zhou J, Huang H, Adeyemo A, Rotimi CN. Paradoxical hyperadiponectinemia is associated with the metabolically healthy obese (MHO) phenotype in African Americans. J Endocrinol Metab. 2012;2(2):51-65.
11. Aguilar-Salinas CA, García EG, Robles L, et al. High adiponectin concentrations are associated with the metabolically healthy obese phenotype. J Clin Endocrinol Metab. 2008;93(10):4075-4079.
12. Morrison JA, Glueck CJ, Daniels S, Wang P, Horn P, Stroop D. Paradoxically high adiponectin and the healthy obese phenotype in obese black and white 16-year-old girls. Transl Res. 2010;156(5): 302-308.
13. Guenther M, James R, Marks J, Zhao S, Szabo A, Kidambi S. Adiposity distribution influences circulating adiponectin levels. Transl Res. 2014;164(4):270-277.
14. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev. 1994;74(4):761-811.
15. KissebahAH,SonnenbergGE,MyklebustJ, et al. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci U S A. 2000;97(26):14478-14483.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
18. Comuzzie AG, Tejero ME, et al. The genes influencing adiponectin levels also influence risk factors for metabolic syndrome and type 2 diabetes. Hum Biol. 2007;79(2):191-200.
19. Natarajan S, Lipsitz S, Parzen M, Lipshultz S. A measure of partial association for generalized estimating equations. Stat Modelling. 2007;7(2):175-190.
20. Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: Association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007;116(1):39-48.
21. Snijder MB, Dekker JM, Visser M, et al. Associations of hip and thigh circumferences independent of waist circumference with the incidence of type 2 diabetes: The Hoorn Study. Am J Clin Nutr. 2003;77(5):1192-1197.
22. Porter SA, Massaro JM, Hoffmann U, Vasan RS, O'Donnel CJ, Fox CS. Abdominal subcutaneous adipose tissue:Aprotective fat depot? Diabetes Care. 2009;32(6):1068-1075.
23. Arner P. Not all fat is alike. Lancet. 1998;351(9112):1301-1302.
24. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab. 2000;11(8):327-332.
25. Frühbeck G, Gómez-Ambrosi J, Muruzábal FJ, Burrell MA. The adipocyte: A model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab. 2001;280(6):E827-E847.
26. Balistreri CR, Caruso C, Candore G. The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators Inflamm. 2010;2010:802078.
27. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature. 2006;444(7121):847-853.
28. Eglit T, Ringmets I, Lember M. Obesity, high-molecular-weight (HMW) adiponectin, and metabolic risk factors: Prevalence and gender-specific associations in Estonia. PLoS One. 2013;8(9):e73273.
29. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20(6):1595-1599.
30. Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes. 2005;54(2):534-539.
31. Turer AT, Scherer PE. Adiponectin: Mechanistic insights and clinical implications. Diabetologia. 2012;55(9):2319-2326.
32. Ziemke F, Mantzoros CS. Adiponectin in insulin resistance: Lessons from translational research. Am J Clin Nutr. 2010;91(1):258S-261S.
33. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer:Areview of current evidence. Endocr Rev. 2012; 33(4):547-594.
34. Carey VJ, Walters EE, Colditz GA, et al. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study. Am J Epidemiol. 1997;145(7):614-619.
35. Motoshima H, Wu X, Sinha MK, et al. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: Effects of insulin and rosiglitazone. J Clin Endocrinol Metab. 2002;87(12):5662-5667.
36. Bremer AA, Devaraj S, Afify A, Jialal I. Adipose tissue dysregulation in patients with metabolic syndrome. J Clin Endocrinol Metab. 2011;96(11):E1782-E1788.
37. McLaughlin T, Lamendola C, Liu A, Abbasi F. Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity. J Clin Endocrinol Metab. 2011;96(11):E1756-E1760.
38. Vansaun MN. Molecular pathways: Adiponectin and leptin signaling in cancer. Clin Cancer Res. 2013;19(8):1926-1932.
39. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003; 423(6941):762-769.
40. Yamauchi T, Nio Y, Maki T, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007;13(3):332-339.
41. Bjursell M, Ahnmark A, Bohlooly-Y M, et al. Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. Diabetes. 2007;56(3):583-593.
42. Arita Y, Kihara S, Ouchi N, et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derivedgrowthfactor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation. 2002;105(24):2893-2898.
43. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation. 2000;102(11):1296-1301.
44. Shibata R, Sato K, Pimentel DR, et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK-and COX-2-dependent mechanisms. Nat Med. 2005;11(10):1096-1103.
45. Kwon BJ, Kim DW, Her SH, et al. Metabolically obese status with normal weight is associated with both the prevalence and severity of angiographic coronary artery disease. Metabolism. 2013;62(7): 952-960.
46. Kim S, Lee H, Lee DC, Lee HS, Lee JW. Predominance of small dense LDLdifferentiates metabolically unhealthy from metabolically healthy overweight adults in Korea. Metabolism. 2014;63(3):415-421.